Idiopathic Pulmonary Fibrosis Clinical Trial
Official title:
Clinical, Radiological Characteristics and Health Related Quality of Life in Idiopathic Pulmonary Fibrosis Patients
Idiopathic pulmonary fibrosis is defined as a specific form of chronic, progressive
fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults,
limited to the lungs, and associated with the histopathologic and/or radiologic pattern of
usual interstitial pneumonia.
The definition of Idiopathic pulmonary fibrosis requires the exclusion of other forms of
interstitial pneumonia including other idiopathic interstitial pneumonias and Interstitial
lung disease associated with environmental exposure, medication, or systemic disease.
Prevalence estimates for Idiopathic pulmonary fibrosis have varied from 2 to 29 cases per
100,000 in the general population IPF should be considered in all adult patients with
unexplained chronic exertional dyspnea, and commonly presents with cough, bibasilar
inspiratory crackles, and finger clubbing.
Idiopathic pulmonary fibrosis should be considered in all adult patients with unexplained
chronic exertional dyspnea, and commonly presents with cough, bibasilar inspiratory
crackles, and finger clubbing.
High resolution chest computed tomography is an essential component of the diagnostic
pathway in Idiopathic pulmonary fibrosis. usual interstitial pneumonia is characterized on
high resolution chest computed tomography by the presence of reticular opacities, often
associated with traction bronchiectasis.
Patients with interstitial lung disease have poor health-related quality of life. However,
whether health-related quality of life differs among different subtypes of interstitial lung
disease is unclear.
There is limited research on the health-related quality of life of Idiopathic pulmonary
fibrosis patients.
Health-related quality of life deficits should be monitored in clinical practice with
Idiopathic pulmonary fibrosis patients and considered when investigating new therapies
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
| Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
| Not yet recruiting |
NCT06241560 -
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
|
Phase 2 | |
| Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
| Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
| Completed |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
| Not yet recruiting |
NCT06422884 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
|
Phase 2 | |
| Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
| Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
| Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
| Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
| Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
| Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 |